截至 2026-09-30(2026-11-16 向 SEC 提交的 13F),Peter Kolchinsky(科尔钦斯基) 管理的 RA Capital Management(RA 资本) 披露 92 只美股持仓,申报总市值 $9.97B。前五大持仓:ASND 23.5%、PBLS 9.5%、PCVX 6.5%、RYTM 6.4%、EWTX 3.4%。本期变化:新建仓 AMLX、LTGO、OBX、DBVT、AGEN、SCTX、KRSA、ETRA、SGMT、IKT;清仓 BCRX、NUVALENT INC-A、NTLA、DFTX、AKTS、BIOA、KPTI、WAY、CRVS、HOWL;主要加仓 FRNM、VOR、TSHA、CAPR、PBLS;主要减仓 SION、GHRS、ZLAB、SEPN、JBIO。
彼得·科尔钦斯基(Peter Kolchinsky),2001 年在波士顿创立 RA 资本,专注生物医药,公开市场与私募投资并行,常在上市前后持续支持被投公司。13F 只披露美股多头。
| # | 代码 | 公司 | 权重 | 市值 | 股数 | 本期 |
|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | 23.5% | $2.34B | 10,281,496 | 持有 |
| 2 | PBLS | Parabilis Medicines, Inc. | 9.5% | $942.16M | 29,177,964 | 加仓 |
| 3 | PCVX | Vaxcyte, Inc. | 6.5% | $652.90M | 11,474,599 | 持有 |
| 4 | RYTM | Rhythm Pharmaceuticals, Inc. | 6.4% | $634.78M | 6,666,837 | 持有 |
| 5 | EWTX | Edgewise Therapeutics, Inc. | 3.4% | $340.74M | 8,392,730 | 持有 |
| 6 | TYRA | Tyra Biosciences, Inc. | 2.7% | $266.78M | 12,198,625 | 持有 |
| 7 | FRNM | Freenome, Inc. | 2.4% | $242.03M | 15,367,270 | 加仓 |
| 8 | COAG | Hemab Therapeutics Holdings, Inc. | 2.4% | $240.82M | 7,808,627 | 持有 |
| 9 | NAMS | NewAmsterdam Pharma Company N.V. | 2.3% | $232.26M | 9,550,191 | 持有 |
| 10 | SEPN | Septerna, Inc. | 2.2% | $215.33M | 5,502,858 | 减仓 |
| 11 | SGP | SpyGlass Pharma, Inc. | 2.1% | $208.55M | 8,021,117 | 持有 |
| 12 | JANX | Janux Therapeutics, Inc. | 1.9% | $193.36M | 11,189,693 | 持有 |
| 13 | MLYS | Mineralys Therapeutics, Inc. | 1.9% | $193.32M | 7,692,750 | 持有 |
| 14 | IRON | Disc Medicine, Inc. | 1.6% | $160.39M | 2,450,221 | 持有 |
| 15 | TSHA | Taysha Gene Therapies, Inc. | 1.5% | $148.22M | 30,435,190 | 加仓 |
| 16 | BCAX | Bicara Therapeutics Inc. | 1.4% | $135.03M | 7,255,993 | 持有 |
| 17 | ARTV | Artiva Biotherapeutics, Inc. | 1.3% | $131.64M | 18,489,293 | 加仓 |
| 18 | XNCR | Xencor, Inc. | 1.3% | $131.59M | 5,274,274 | 持有 |
| 19 | ORKA | Oruka Therapeutics, Inc. | 1.3% | $129.48M | 1,554,597 | 持有 |
| 20 | AMLX | Amylyx Pharmaceuticals, Inc. | 1.2% | $124.53M | 4,279,341 | 建仓 |
| 21 | CLYM | Climb Bio, Inc. | 1.2% | $116.19M | 10,130,130 | 减仓 |
| 22 | ABVX | ABIVAX Société Anonyme | 1.0% | $102.00M | 1,030,058 | 减仓 |
| 23 | WVE | Wave Life Sciences, Inc. | 1.0% | $99.81M | 26,975,505 | 持有 |
| 24 | LTGO | Latigo Biotherapeutics, Inc. | 0.9% | $88.56M | 5,302,933 | 建仓 |
| 25 | SLDB | Solid Biosciences Inc. | 0.9% | $87.02M | 12,036,126 | 持有 |
| 26 | VOR | Vor Biopharma Inc. | 0.9% | $85.93M | 4,503,882 | 加仓 |
| 27 | LBRX | LB Pharmaceuticals Inc | 0.9% | $84.77M | 2,208,604 | 持有 |
| 28 | GHRS | GH Research PLC | 0.8% | $84.74M | 3,609,007 | 减仓 |
| 29 | OBX | Obsidian Therapeutics, Inc. | 0.8% | $81.79M | 5,957,103 | 建仓 |
| 30 | ZLAB | 再鼎医药 (Zai Lab) | 0.7% | $74.16M | 2,815,543 | 减仓 |
数据来源:SEC EDGAR 13F-HR 公开申报。13F 只披露季度末的美股多头仓位,提交期限为季度结束后 45 天,不含空头、现金和非美股资产;不构成投资建议。 原始申报:SEC EDGAR 0001104659-26-128411。 机器可读数据:kolchinsky.json。